SCHEMBL3936873

SCHEMBL3936873

CCOC(=O)COc1ccc([N+](=O)[O-])c(Oc2cc(C#N)cc(OC)c2)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 6/20 0.39
MAPT P10636 6/20 0.39
LMNA P02545 4/20 0.39
HPGD P15428 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
NTSR1 P30989 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
F2 P00734 1/20 0.38
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
S1PR4 O95977 1/20 0.36
ITGA4 P13612 1/20 0.36
S1PR1 P21453 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14304694 0.95 MAPT (0.40) SMN1; SMN2ALDH1A1MAPTLMNAHPGD
SCHEMBL14304210 0.91 MAPT (0.42) SMN1; SMN2ALDH1A1MAPTLMNAHPGD
SCHEMBL14304695 0.91 MAPT (0.39) SMN1; SMN2ALDH1A1MAPTLMNAHPGD
SCHEMBL3640135 0.81 MAPT (0.35) SMN1; SMN2ALDH1A1MAPTLMNAHPGD
SCHEMBL14300496 0.80 MAPT (0.38) ALDH1A1MAPTLMNACYP2C19CYP3A4
SCHEMBL3640707 0.79 MAPT (0.44) ALDH1A1MAPTHPGDCYP2C19CYP3A4
SCHEMBL3636393 0.78 MAPT (0.39) SMN1; SMN2ALDH1A1MAPTLMNANPSR1
SCHEMBL14476311 0.78 MEN1 (0.47) SMN1; SMN2ALDH1A1MAPTLMNAHPGD
SCHEMBL14570952 0.78 KCNH2 (0.37) ALDH1A1MAPTLMNACYP2C19CYP3A4
SCHEMBL14318645 0.77 CYP3A4 (0.52) ALDH1A1HPGDNPSR1CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046731-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP disclosed
WO-2008009613-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-24 WO disclosed
US-20080020981-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080020981-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, HPRT1, NQO2 SMN1; SMN2 3307/4885ALDH1A1 566/4885MAPT 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.